nitazoxanid
broadspectrum
antivir
agent
undergo
clinic
develop
treatment
influenza
viral
respiratori
infect
nitazoxanid
exhibit
vitro
activ
middl
east
respiratori
syndrom
coronaviru
merscov
coronavirus
inhibit
express
viral
n
protein
nitazoxanid
also
suppress
product
proinflammatori
cytokin
peripher
blood
mononuclear
cell
suppress
interleukin
product
mice
use
extens
clinic
trial
postmarket
experi
nitazoxanid
attract
drug
candid
treatment
middl
east
respiratori
syndrom
futur
research
includ
vitro
mechan
studi
anim
model
merscov
infect
clinic
trial
includ
doserang
trial
evalu
combin
therapi
potenti
merscov
antivir
middl
east
respiratori
syndrom
coronaviru
merscov
emerg
viral
diseas
global
concern
three
year
first
discoveri
merscov
fundament
question
relat
epidemiolog
pathogenesi
immun
respons
optim
treatment
remain
unansw
nevertheless
associ
high
rate
mortal
approv
antivir
treatment
hostdirect
therapi
repurpos
exist
drug
propos
promis
strategi
develop
merscovspecif
antivir
therapi
nitazoxanid
broadspectrum
antivir
agent
undergo
develop
treatment
influenza
viral
respiratori
infect
origin
develop
antiprotozo
agent
immediatereleas
dosag
formul
nitazoxanid
licens
unit
state
http
treatment
intestin
infect
caus
cryptosporidium
parvum
throughout
latin
america
india
bangladesh
egypt
broadspectrum
antiparasit
agent
new
extendedreleas
oral
tablet
develop
deliv
drug
system
nitazoxanid
repurpos
use
treat
viral
respiratori
infect
present
undergo
phase
clinic
develop
treat
acut
uncompl
influenza
vitro
tizoxanid
activ
circul
metabolit
nitazoxanid
inhibit
replic
broad
rang
influenza
b
strain
includ
influenza
subtyp
oseltamivirand
amantadineresist
strain
concentr
requir
inhibit
viral
replic
ic
gml
multipl
human
canin
cell
line
use
singlestep
viru
growth
high
multipl
infect
pfucel
multistep
growth
low
multipl
infect
pfucel
ic
concentr
easili
achiev
human
follow
administr
nitazoxanid
extendedreleas
tablet
peak
trough
plasma
concentr
repeat
twice
daili
dose
report
gml
respect
tizoxanid
act
synergist
oseltamivir
zanamivir
inhibit
vitro
replic
influenza
virus
exhibit
high
barrier
resist
decreas
sensit
influenza
virus
passag
day
increasingli
subinhibitori
concentr
drug
addit
influenza
virus
tizoxanid
inhibit
replic
broad
rang
rna
dna
virus
cell
cultur
assay
includ
respiratori
syncyti
viru
parainfluenza
coronaviru
rotaviru
noroviru
hepat
b
hepat
c
dengu
yellow
fever
japanes
enceph
viru
human
immunodefici
viru
broadspectrum
antivir
activ
tizoxanid
attribut
interfer
hostregul
pathway
involv
viral
replic
rather
virustarget
mechan
pathway
may
includ
interferon
signal
pathway
case
influenza
tizoxanid
ultim
block
matur
viral
hemagglutinin
posttransl
stage
affect
neuraminidas
glycoprotein
target
oseltamivir
zanamivir
peramivir
protein
target
amantadin
effect
viral
infect
adsorpt
entri
target
cell
importantli
nitazoxanid
studi
extens
human
undergon
preclin
clinic
test
requir
licensur
unit
state
treatment
diarrhea
caus
cryptosporidium
parvum
giardia
lamblia
exposur
clinic
trial
includ
specif
experi
patient
influenza
influenzalik
ill
extend
cours
treatment
week
patient
chronic
hepat
c
worldwid
estim
million
peopl
treat
nitazoxanid
treatment
intestin
parasit
infect
vitro
studi
shown
tizoxanid
inhibit
replic
canin
coronaviru
grown
cell
ic
gml
studi
shown
nitazoxanid
inhibit
murin
coronaviru
mous
hepat
viru
strain
bovin
coronaviru
strain
human
enter
coronaviru
grown
mous
astrocytoma
dbt
fibroblast
cell
ic
approxim
gml
studi
nitazoxanid
inhibit
express
viral
n
protein
parent
compound
nitazoxanid
metabolit
tizoxanid
gener
show
similar
inhibitori
activ
virus
vitro
compound
shown
inhibit
merscov
cultur
cell
ic
gml
nitazoxanid
tizoxanid
respect
notabl
vitro
ic
similar
observ
influenza
virus
addit
antivir
activ
nitazoxanid
inhibit
product
proinflammatori
cytokin
peripher
blood
mononuclear
cell
pbmc
romark
laboratori
person
commun
vivo
oral
administr
nitazoxanid
mice
dose
mgkg
given
two
hour
intraperiton
inject
thioglycol
tg
reduc
plasma
level
six
hour
tg
inject
compar
vehicletr
mice
relev
data
human
studi
data
suggest
nitazoxanid
could
improv
outcom
patient
infect
merscov
suppress
overproduct
proinflammatori
cytokin
includ
nitazoxanid
extendedreleas
tablet
current
undergo
clinic
develop
treatment
acut
uncompl
influenza
phase
random
doubleblind
placebo
control
trial
conduct
outpati
clinic
unit
state
decemb
may
subject
year
age
fever
c
least
one
respiratori
symptom
one
constitut
symptom
influenza
enrol
within
h
symptom
onset
flu
circul
commun
subject
vaccin
season
influenza
highrisk
influenzarel
complic
exclud
subject
receiv
either
mg
nitazoxanid
mg
nitazoxanid
placebo
oral
twice
daili
five
day
follow
day
subject
maintain
diari
grade
nine
symptom
absent
mild
moder
sever
twice
daili
seven
day
longer
symptom
return
absent
mild
day
primari
endpoint
time
first
dose
allevi
symptom
symptom
mild
moder
least
h
primari
analysi
intentiontotreat
subject
influenza
infect
confirm
rtpcr
cultur
baselin
total
subject
enrol
influenza
identifi
nasopharyng
swab
collect
baselin
subject
receiv
nitazoxanid
experienc
shorter
time
allevi
symptom
compar
subject
receiv
placebo
median
time
first
dose
symptom
allevi
h
ci
p
subject
receiv
mg
nitazoxanid
h
ci
p
subject
receiv
mg
nitazoxanid
compar
h
ci
subject
receiv
placebo
lack
statist
signific
low
dose
group
may
due
lack
statist
power
advers
event
similar
three
group
common
headach
report
subject
placebo
group
subject
lowdos
group
subject
highdos
group
diarrhea
report
subject
placebo
group
subject
lowdos
group
subject
highdos
group
base
upon
data
phase
trial
nitazoxanid
extendedreleas
tablet
mg
administ
twice
daili
five
day
undergo
phase
clinic
develop
treatment
acut
uncompl
influenza
nitazoxanid
studi
monotherapi
combin
oseltamivir
exist
data
suggest
potenti
role
nitazoxanid
treat
merscov
includ
vitro
activ
nitazoxanid
merscov
coronavirus
ii
inhibit
proinflammatori
cytokin
pbmc
inhibit
product
mice
iii
activ
reduc
durat
symptom
influenza
human
iv
favor
safeti
profil
demonstr
clinic
trial
widespread
postmarket
use
futur
research
includ
vitro
studi
effect
nitazoxanid
viral
protein
elucid
mechan
action
coronavirus
fund
sourc
